In this study, we assessed the effects of PD180970, a TKI targeting breakpoint cluster region-Abelson murine leukemia (Bcr-Abl), and cabozantinib, a TKI targeting vascular endothelial growth factor receptor 2 (VEGFR2), on AD pathologies and compared their therapeutic efficacies with that of ibrutinib in 5xFAD mice, a mouse model of AD. The gene discussed is KDR; the disease is Alzheimer disease.